Ashland reports financial results for fourth-quarter fiscal 20241, issues outlook for full-year fiscal 2025, provides portfolio optimization update and announces strategy update event
| AVXL Stock | USD 9.46 0.43 4.76% |
About 61% of all Anavex Life's institutional investors are looking to take a long position. The analysis of the overall investor sentiment regarding Anavex Life Sciences suggests that some traders are interested. Anavex Life's investing sentiment shows overall attitude of investors towards Anavex Life Sciences.
Anavex |
Financial results for fourth-quarter fiscal 20241 Sales of 522 million, up one percent from the prior-year quarterSold nutraceuticals business to Turnspire Capital Partners LLCPreviously announced carboxymethylcellulose , methylcellulose and nutraceuticals portfolio optimization initiatives reduced overall sales by approximately 24 million or five percent versus the prior-year quarterIncome from continuing operations of 19 million, or 0. per diluted shareAdjusted income from cont
Read at finance.yahoo.com
 |
Anavex Life Fundamental Analysis
We analyze Anavex Life's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Anavex Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Anavex Life based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earning
Price To Earning Comparative Analysis
Anavex Life is currently under evaluation in price to earning category among its peers. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Anavex Life Sciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Anavex Life stock to make a market-neutral strategy. Peer analysis of Anavex Life could also be used in its relative valuation, which is a method of valuing Anavex Life by comparing valuation metrics with similar companies.
Peers
Anavex Life Related Equities
| SAVA | Cassava Sciences | 3.92 | ||||
| INMB | INmune Bio | 3.27 | ||||
| RNAZ | Transcode Therapeutics | 2.94 | ||||
| ANVS | Annovis Bio | 2.60 | ||||
| KOD | Kodiak Sciences | 1.83 | ||||
| EXEL | Exelixis | 1.48 | ||||
| NVAX | Novavax | 1.16 | ||||
| TGTX | TG Therapeutics | 0.57 | ||||
| IOVA | Iovance Biotherapeutics | 0.85 | ||||
| MDGL | Madrigal Pharmaceuticals | 0.98 | ||||
| AXSM | Axsome Therapeutics | 1.44 | ||||
| CGTX | Cognition Therapeutics | 2.44 | ||||
| VKTX | Viking Therapeutics | 2.88 | ||||
| BIVI | Biovie | 3.90 | ||||
| RVPHW | Reviva Pharmaceuticals | 4.35 | ||||
| BTAI | BioXcel Therapeutics | 8.89 |
Check out Anavex Life Hype Analysis, Anavex Life Correlation and Anavex Life Performance. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anavex Life. If investors know Anavex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anavex Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.51) | Return On Assets (0.20) | Return On Equity (0.30) |
The market value of Anavex Life Sciences is measured differently than its book value, which is the value of Anavex that is recorded on the company's balance sheet. Investors also form their own opinion of Anavex Life's value that differs from its market value or its book value, called intrinsic value, which is Anavex Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anavex Life's market value can be influenced by many factors that don't directly affect Anavex Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anavex Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Anavex Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anavex Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.